Outcomes of venetoclax combined with homoharringtonine and cytarabine in fit adults patients with de novo adverse‐risk acute myeloid leukaemia: A single‐centre retrospective analysis

Adverse‐risk acute myeloid leukemia (AML) has a dismal prognosis. We aimed to investigate the activity and tolerability of venetoclax combined with homoharringtonine (HHT) plus cytarabine (VHA) regimen for de novo adverse‐risk AML. Thirteen de novo AML patients with adverse‐risk factors were treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Bao‐Quan, Kong, Xin, Pu, Yan, Liu, Yin, Zhang, Jian, Wu, De‐Pei, Qiu, Hui‐Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660102/
https://www.ncbi.nlm.nih.gov/pubmed/38024627
http://dx.doi.org/10.1002/jha2.792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660102/
https://www.ncbi.nlm.nih.gov/pubmed/38024627
http://dx.doi.org/10.1002/jha2.792

Ejemplares similares